The Commission has published a joint clinical assessment (JCA) report on camizestrant (Etcamah), a medicinal product for the treatment of breast cancer.
The assessment was carried out by the competent authorities of Austria and Belgium under the EU Health Technology Assessment (HTA) Regulation.
The JCA report published on November 6 was endorsed by the Member States on 19 August 2026.
The Commission granted marketing authorisation for this product on 20 July 2026.
Joint Clinical Assessments allow EU Member States to work together to assess the clinical benefits of new medicines and certain medical devices compared to existing health technologies. Patients and clinical experts are systematically consulted during this process.
The outcome is a joint clinical assessment report and summary report. These reports will be used by Member States in their national decision-making procedures.

Further joint clinical assessment reports will be published in the coming months on the Commission’s HTA website.
JCA tracker table
is updated regularly and provides the list of ongoing joint clinical assessments.






